Ignite Creation Date:
2025-12-24 @ 2:02 PM
Ignite Modification Date:
2025-12-27 @ 9:54 PM
Study NCT ID:
NCT01415895
Status:
COMPLETED
Last Update Posted:
2021-04-14
First Post:
2011-08-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001416', 'term': 'Back Pain'}, {'id': 'D017116', 'term': 'Low Back Pain'}, {'id': 'D019547', 'term': 'Neck Pain'}, {'id': 'D009437', 'term': 'Neuralgia'}], 'ancestors': [{'id': 'D010146', 'term': 'Pain'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D010523', 'term': 'Peripheral Nervous System Diseases'}, {'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D009271', 'term': 'Naltrexone'}], 'ancestors': [{'id': 'D009270', 'term': 'Naloxone'}, {'id': 'D009019', 'term': 'Morphinans'}, {'id': 'D053610', 'term': 'Opiate Alkaloids'}, {'id': 'D000470', 'term': 'Alkaloids'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D006572', 'term': 'Heterocyclic Compounds, Bridged-Ring'}, {'id': 'D006576', 'term': 'Heterocyclic Compounds, 4 or More Rings'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D010616', 'term': 'Phenanthrenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 78}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2011-07'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-04', 'completionDateStruct': {'date': '2013-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-04-11', 'studyFirstSubmitDate': '2011-08-11', 'studyFirstSubmitQcDate': '2011-08-11', 'lastUpdatePostDateStruct': {'date': '2021-04-14', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2011-08-12', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-02', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from Baseline in Brief Pain Inventory 24-hour Pain Scores for average pain (Question #5)', 'timeFrame': 'baseline to week 3', 'description': 'The Brief Pain Inventory is a self-reported medical questionnaire used to measure pain over the past 24-hours - worst pain (Question 3), least pain (Question 4), average pain (Question 5), right now pain (Question 6) and at night pain (Question 7). The score ranges from 0 to 10 (0 - no pain) (10 - intolerable pain).'}], 'secondaryOutcomes': [{'measure': 'Change from Baseline in Brief Pain Inventory 24-hour assessment of interference in function (Questions 9a - 9i).', 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': 'BPI Interference; questions 9a - 9i - measures a self-reported assessment of the interference in function because of pain in past 24 hours in general activity, mood, walking ability, normal work, relationship with other people, sleep quality, enjoyment of life, standing ability and sitting ability. Interference scores: 0 (does not interfere) to 10 (completely interferes).'}, {'measure': "Change From Baseline in Brief Pain Inventory 24-hour subject's Global Impression of Improvement (Question 8)", 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': "The Brief Pain Inventory question 8 measures the subject's perception of how much relief he has received at the time of assessment compared with before the start of the study drug. The score is measured in percentage 0% (no relief) to100% (complete relief)."}, {'measure': "Change From Baseline in the subject's Global Assessment of Treatment Satisfaction today", 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': 'A self-reported scale that measures Treatment Satisfaction today in (0-10, 0 - none, 10 - most satisfied)'}, {'measure': "Change from Baseline in the subject's perception of Ability to Tolerate the study drug and the severity of side effects today.", 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': 'A self-reported scale that measures the ability to tolerate the study drug and the severity of side effects today in (0-10, 0 - No side effects, 10 - intolerable side effects)'}, {'measure': 'Change From Baseline in Oswestry Disability Index and Neck Disability composite scores(ODI), to Week 1, Week 2, and Week 3', 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': 'The Oswestry Low Back Pain Disability Questionnaire (Oswestry Disability Index) and Neck Disability composite assesses pain-related disability in persons with low back pain (LBP) and neck pain. The score is recorded in percentage of disability.'}, {'measure': 'Change From Baseline in Roland Morris Disability Questionnaire composite scores(ODI), to Week 1, Week 2, and Week 3', 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': 'The Roland Morris Disability Questionnaire consists of 24 statements and the subject is instructed to put a mark next to each appropriate statement. The total score ranges from 0 (no disability) to 24 (severe disability).'}, {'measure': 'Change From Baseline in Vital Signs - systolic blood pressure, diastolic blood pressure, pulse rate and body mass index to Week 1, Week 2, and Week 3.', 'timeFrame': 'baseline to week 1, week 2 and week 3'}, {'measure': 'Change from Baseline to week 3 in Laboratory Assessments - Alkaline Phosphatase, Alanine Transaminase - ALT (SGPT), Aspartate transaminase - AST(SGOT), Bilirubin, Total, Serum Creatinine, Blood Urea Nitrogen, Serum Chloride, Potassium, HCO3', 'timeFrame': 'baseline to week 1, week 2 and week 3'}, {'measure': "Change from Baseline in the investigator's Clinical Global Impression - Severity scale (CGI-S) to Week 1, Week 2, week 3 .", 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': "The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the investigator to rate the severity of the subject's back pain at the time of assessment, relative to the investigator's past experience. Considering total clinical experience, the subject is assessed on severity of back pain at the time of rating 1, normal; 2, borderline; 3, mild; 4, moderate; 5, marked; 6, severe; or 7, extreme."}, {'measure': "Change from Baseline in The investigator's Clinical Global Impression - Improvement scale (CGI-I) to Week 1, Week 2, week 3", 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': "The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale, the investigator will rate how much the patient's back pain has improved or worsened relative to a baseline state at the beginning of the study and rate as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse."}, {'measure': 'Change from Baseline in the subject\'s answer to the question, "Are you better off today then the time before starting the study drug?, yes/no, by what percentage?', 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': 'Answer, yes/no and by 0%-100% (0%-not at all better, 100% - very much better off'}, {'measure': 'Change From Baseline in the subject\'s answer to the question " Have you been more / less active in the past 24 hrs, comparing to the period before initiating the study drug, please rate in %.', 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': 'The subjects answer, one of the following choices, - 150%, -100%, -50%, - 25%, 0% - same activity level, +25%, +50%, +100%, +150%'}, {'measure': 'Subject\'s response to the question, "Have you responded to the treatment?"', 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': "Subject's answer yes/no."}, {'measure': "Subject's Global Assessment of Disease Activity Improved / No Change", 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': 'The Subject answer either Improved or No Change.'}, {'measure': "Subject's Global Evaluation of Study Medication.", 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': 'The subject chooses, 1 - Excellent, 2 - Very Good, 3 - Good, 4 - Fair, 5 - Poor'}, {'measure': "The Subject's Satisfaction with Pain Relief, 0 - 10.", 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': 'The subject answers on a scale of 0-10, (0 - not satisfied, 10 - very satisfied).'}, {'measure': "The Subject's Satisfaction with Moving, Standing, Walking and Bending Ability Scale, 0-10.", 'timeFrame': 'baseline to week 1, week 2 and week 3.', 'description': 'The subjects answers on a scale of 0-10, (0 - not satisfied, 10 - very satisfied)'}, {'measure': 'Change from Baseline in Brief Pain Inventory 24-hour Pain Scores for worst pain, least pain, right now pain and night pain (Questions 3,4,6 & 7)', 'timeFrame': 'baseline to week 1, week 2 and week 3', 'description': 'The Brief Pain Inventory is a self-reported medical questionnaire used to measure pain over the past 24-hours - worst pain (Question 3), least pain (Question 4), average pain (Question 5), right now pain (Question 6) and at night pain (Question 7). The score ranges from 0 to 10 (0 - no pain) (10 - intolerable pain).'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['back pain', 'cervical pain', 'neuropathic pain', 'radicular pain'], 'conditions': ['Back Pain', 'Lower Back Pain', 'Cervical Pain']}, 'descriptionModule': {'briefSummary': 'The study includes back pain of the cervical, thoracic, and the lumbar regions.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '19 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nThe subject has chronic back pain for \\> 3 months in the lumbar, thoracic or cervical regions.\n\nThe average pain intensity scale during the screening week is 4/10 - 8/10 (On an 11-point Numeric Pain Intensity Scale with 0 = no pain and 10 = worst pain imaginable).\n\nThe subject has not taken Opioid medications 7 days prior to initiation of study drug.\n\nThe subject has a heart rate of 60bpm or above and/or systolic blood pressure 90 or above.\n\nThe subject is willing to refrain from using NSAIDS, Acetaminophen or muscle relaxants, unless for rescue, for the duration of the study The subject is willing to refrain from using Opioid medications and excessive alcohol for the duration of the study.\n\nThe subject is able to read, understand and follow the study instructions, including completion of questionnaires at home.\n\nThe subject must sign an informed consent document indicating willingness to participate.\n\nIf the subject is a female, she must be post-menopausal, not currently pregnant or nursing. A female of child bearing potential should be using a reliable contraception method during the course of the study.\n\nExclusion Criteria:\n\nThe subject has a positive urine drug screen. The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.\n\nThe subject has any significant deviations from normal in physical examination, electrocardiogram (ECG), Echocardiogram or clinical laboratory tests, as evaluated by the investigator.\n\nThe subject has a history of an allergic reaction to the components of the study drug.\n\nThe subject has acute back or cervical pain. The subject has muscular back or cervical pain. The subject has back or cervical pain other than chronic Radicular pain.'}, 'identificationModule': {'nctId': 'NCT01415895', 'briefTitle': 'Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain', 'organization': {'class': 'INDUSTRY', 'fullName': 'Allodynic Therapeutics, Inc'}, 'officialTitle': 'A Proof-of-Concept, Randomized, Double-Blind and Placebo Controlled Clinical Trial With Naltrexone and Clonidine Combination (ATNC05) Compared With Placebo in the Treatment of Chronic Back Pain', 'orgStudyIdInfo': {'id': 'AT110491'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'ATNC05 - a study drug capsule', 'description': 'Naltrexone and Clonidine Combination (ATNC05)', 'interventionNames': ['Drug: Naltrexone and Clonidine Combination']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'placebo', 'interventionNames': ['Drug: placebo']}], 'interventions': [{'name': 'Naltrexone and Clonidine Combination', 'type': 'DRUG', 'otherNames': ['ATNC05'], 'description': 'subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.', 'armGroupLabels': ['ATNC05 - a study drug capsule']}, {'name': 'placebo', 'type': 'DRUG', 'description': 'subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.', 'armGroupLabels': ['placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '33181', 'city': 'North Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Annette C. Toledano MD', 'geoPoint': {'lat': 25.89009, 'lon': -80.18671}}], 'overallOfficials': [{'name': 'Annette C Toledano, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Allodynic Therapeutics, Inc'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Annette C. Toledano MD', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Sponsor/Investigator', 'investigatorFullName': 'Annette C. Toledano MD', 'investigatorAffiliation': 'Allodynic Therapeutics, Inc'}}}}